Frontal Fibrosing Alopecia Clinical Trial
Official title:
Follicular Revival in Fibrosing Alopecia: Evaluating Use of Micro-needling
| NCT number | NCT04342091 |
| Other study ID # | 2000027405 |
| Secondary ID | |
| Status | Completed |
| Phase | N/A |
| First received | |
| Last updated | |
| Start date | April 9, 2021 |
| Est. completion date | April 8, 2022 |
| Verified date | March 2023 |
| Source | Yale University |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
To evaluate the efficacy microneedling via a professional tattoo machine in revitalizing hair follicles in patients with fibrosing alopecia.
| Status | Completed |
| Enrollment | 6 |
| Est. completion date | April 8, 2022 |
| Est. primary completion date | April 8, 2022 |
| Accepts healthy volunteers | Accepts Healthy Volunteers |
| Gender | Female |
| Age group | 18 Years and older |
| Eligibility | Inclusion Criteria: - Healthy Female - Diagnosing Fibrosing alopecia Exclusion Criteria: - Any female with hair loss for other reasons - Males - Patients with cardiac conditions or renal insufficiency - Pregnant patients - Patients containing the following who would make poor candidates for microneedling, such as skin conditions, diabetes, history of keloid formation - Anything additional existing comorbidities that in the opinion of the investigator may cause unnecessary risk for the patient to participate |
| Country | Name | City | State |
|---|---|---|---|
| United States | Yale University | New Haven | Connecticut |
| Lead Sponsor | Collaborator |
|---|---|
| Yale University |
United States,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Total Area Hair Count (Frontal) | Total number of hairs over an area of 1cm^2 | 6 months | |
| Primary | Total Area Hair Count (Vertex) | Total number of hairs over an area of 1 cm^2 | 6 months | |
| Secondary | Hair Shaft Diameters (Frontal) | Hair shaft diameter measured per trichoscopy | 6 months | |
| Secondary | Hair Shaft Diameters (Vertex) | Hair shaft diameter measured per trichoscopy | 6 months | |
| Secondary | Number of Hair Follicles (Frontal) | Number of hair follicles counted per 1cm^2 | 6 months | |
| Secondary | Number of Hair Follicles (Vertex) | Number of hair follicles per 1 cm^2 | 6 months | |
| Secondary | Vellus Hairs (Frontal) | Number of vellus hairs per cm^2 | 6 months | |
| Secondary | Vellus Hairs (Vertex) | Number of vellus hairs per cm^2 | 6 months | |
| Secondary | Terminal Hairs (Frontal) | Number of terminal hairs over an area of 1 cm^2 | 6 months | |
| Secondary | Terminal Hairs (Vertex) | Number of terminal hairs per area of 1 cm^2 | 6 months |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04409041 -
Oral Low-Dose Naltrexone for Lichen Planopilaris and Frontal Fibrosing Alopecia
|
Phase 2 | |
| Completed |
NCT03630198 -
Pain Outcomes Following Intralesional Corticosteroid Injections
|
Phase 4 | |
| Enrolling by invitation |
NCT06202560 -
Effectiveness and Safety of Tofacitinib in Patients With Recalcitrant Frontal Fibrosing Alopecia : A Pilot Study
|
N/A | |
| Not yet recruiting |
NCT03335228 -
Platelet Rich Plasma for Frontal Fibrosing Alopecia
|
N/A | |
| Not yet recruiting |
NCT02467101 -
Study to Assess the Efficacy of Intralesional Corticosteroid on the Treatment of Frontal Fibrosing Alopecia
|
N/A | |
| Recruiting |
NCT03422640 -
Trial Evaluating the Efficacy of Apremilast for the Treatment of Frontal Fibrosing Alopecia
|
Phase 4 | |
| Completed |
NCT03346668 -
Role of Neurogenic Inflammation and Topical 6% Gabapentin Therapy in Symptomatic Scarring Alopecia
|
Early Phase 1 | |
| Active, not recruiting |
NCT03082560 -
Design and Validation of a New Assessment Tool for Lichen Planopilaris
|
||
| Recruiting |
NCT06240351 -
A Study to Evaluate the Safety and Efficacy of Baricitinib in the Treatment of Frontal Fibrosing Alopecia (FFA)
|
Phase 4 | |
| Completed |
NCT05332366 -
A Trial to Assess the Effect of Delgocitinib Cream 20 mg/g on the Molecular Signature, Safety, and Efficacy in Adults With Frontal Fibrosing Alopecia
|
Phase 2 |